What one share of Mereo Biopharma Group holds
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our late-stage rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (“OI”) and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (“AATD-LD”).
Mereo Biopharma Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.04 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.04 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.00 | −$0.07 | $0.00 | −$0.08 | — | $0.08 |
| 2023 | $0.02 | −$0.04 | $0.00 | −$0.03 | — | $0.07 |
| 2024 | $0.00 | −$0.06 | $0.00 | −$0.04 | — | $0.08 |
| 2025 | $0.00 | −$0.05 | $0.00 | −$0.04 | — | $0.05 |
Common questions about Mereo Biopharma Group
How much does one share of Mereo Biopharma Group earn?
Over the last 12 months, Mereo Biopharma Group lost $0.04 for each share.
Does Mereo Biopharma Group pay a dividend?
Mereo Biopharma Group didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Mereo Biopharma Group’s book value per share?
Mereo Biopharma Group’s book value is $0.04 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Mereo Biopharma Group have?
Each share of Mereo Biopharma Group has $0.04 of cash and investments, as of June 30, 2026.
What is Mereo Biopharma Group’s free cash flow per share?
−$0.03 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Mereo Biopharma Group bought back shares?
Mereo Biopharma Group’s share count rose about 32% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.